News Archive - Navrogen : Navrogen

May 5, 2025

Navrogen Announces Publication on the CA125-Refractory NAV-006 Antibody for the Treatment of Immunosuppressed Follicular Lymphoma

The article describes the negative impact that the Humoral Immuno-Oncology factor CA125 has on rituximab, obinutuzumab and tafasitamab, as well as T-cell engager antibodies, like mosunetuzumab and glofitamab, on...

March 26, 2025

Navrogen Announces Publication and Presentation at the American Association for Cancer Research (AACR) Annual Meeting of a Novel Antibody Engineering Platform

The article describes new criteria for monoclonal antibody and antibody-drug conjugate development to treat cancers over-expressing the humoral immunosuppressive oncology (HIO) factor ICAM-1

April 4, 2024

Navrogen Presents Its Anti-CD20 Antibody NAV-006 and ICAM-1 Refractory Antibody-Drug Conjugate Platform at the 2024 American Association for Cancer Research Conference

Navrogen presents preclinical data on its next-generation anti-CD20 antibody, NAV-006, and ICAM-1 refractory antibody-drug conjugate platform

May 18, 2023

Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers

The article describes new criteria for antibody-drug conjugate development and preclinical efficacy of NAV-001 ADC against mesothelin-expressing tumor types

April 12, 2023

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Meeting

NAV-001 and NAV-003 both target mesothelin, a cell surface protein over-expressed on various malignancies. Certain ADCs and therapeutic antibodies targeting mesothelin are negatively affected by Humoral Immuno-Oncology (HIO) factors...

March 27, 2023

Navrogen and the National Cancer Institute Establish Collaboration to Study the Impact of Immunosuppressive Factor CA125 on Rituximab Effectiveness

Navrogen has established a research collaboration with the U.S. National Cancer Institute to study the potential role of Cancer Antigen-125 (CA125) in causing immunosuppression in patients with hematologic cancers,...